BRNS Stock Overview
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Barinthus Biotherapeutics plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.38 |
52 Week High | US$5.10 |
52 Week Low | US$1.64 |
Beta | -0.48 |
1 Month Change | -15.15% |
3 Month Change | -35.50% |
1 Year Change | 3.48% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -83.12% |
Recent News & Updates
Recent updates
We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth
Jul 07Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality
Nov 17Vaccitech promotes Gemma Brown to CFO
Sep 20Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts
Aug 15Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 13Vaccitech GAAP EPS of $0.41, revenue of $17.06M
Aug 09Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%
May 19Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Apr 03Vaccitech: The Next Big Vaccine Trade
Jun 27Vaccitech EPS misses by $0.69, beats on revenue
Jun 14Shareholder Returns
BRNS | US Biotechs | US Market | |
---|---|---|---|
7D | -1.2% | 0.9% | 0.2% |
1Y | 3.5% | 11.0% | 28.1% |
Return vs Industry: BRNS underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: BRNS underperformed the US Market which returned 28.8% over the past year.
Price Volatility
BRNS volatility | |
---|---|
BRNS Average Weekly Movement | 7.0% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BRNS's share price has been volatile over the past 3 months.
Volatility Over Time: BRNS's weekly volatility has decreased from 16% to 7% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 107 | Bill Enright | https://www.barinthusbio.com |
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company’s development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older.
Barinthus Biotherapeutics plc Fundamentals Summary
BRNS fundamental statistics | |
---|---|
Market cap | US$90.69m |
Earnings (TTM) | -US$73.35m |
Revenue (TTM) | US$802.00k |
115.5x
P/S Ratio-1.3x
P/E RatioIs BRNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BRNS income statement (TTM) | |
---|---|
Revenue | US$802.00k |
Cost of Revenue | US$44.87m |
Gross Profit | -US$44.07m |
Other Expenses | US$29.28m |
Earnings | -US$73.35m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.88 |
Gross Margin | -5,495.26% |
Net Profit Margin | -9,145.51% |
Debt/Equity Ratio | 0% |
How did BRNS perform over the long term?
See historical performance and comparison